Dr. Yardley Discusses Enzalutamide in HR+ Breast Cancer

Denise A. Yardley, MD
Published: Friday, Jan 05, 2018



Denise A. Yardley, MD, senior investigator of breast cancer research, Sarah Cannon Research Institute, discusses the randomized placebo-controlled phase II trial evaluating exemestane with/without enzalutamide (Xtandi) in patients with hormone receptor (HR)-positive breast cancer

The androgen receptor is prevalent in 30% of patients with triple-negative breast cancer (TNBC). The androgen receptor is expressed in 80% to 90% in patients with HR-positive breast cancer. According to Yardley, this could be a target for the management of endocrine-positive breast cancer.

This trial had 2 cohorts. The first cohort had no prior endocrine therapy whereas the other had one prior therapy for patients with advanced disease. With a biomarker evaluation, this study predicted a group that was sensitive to enzalutamide and demonstrated progression-free survival, explains Yardley.
 


Denise A. Yardley, MD, senior investigator of breast cancer research, Sarah Cannon Research Institute, discusses the randomized placebo-controlled phase II trial evaluating exemestane with/without enzalutamide (Xtandi) in patients with hormone receptor (HR)-positive breast cancer

The androgen receptor is prevalent in 30% of patients with triple-negative breast cancer (TNBC). The androgen receptor is expressed in 80% to 90% in patients with HR-positive breast cancer. According to Yardley, this could be a target for the management of endocrine-positive breast cancer.

This trial had 2 cohorts. The first cohort had no prior endocrine therapy whereas the other had one prior therapy for patients with advanced disease. With a biomarker evaluation, this study predicted a group that was sensitive to enzalutamide and demonstrated progression-free survival, explains Yardley.
 

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Cancer Summaries and Commentaries™: Update from Chicago: Advances in the Treatment of Breast CancerJul 31, 20181.0
Community Practice Connections™: Medical Crossfire®: Translating Lessons Learned with PARP Inhibition to the Treatment of Breast Cancer—Expert Exchanges on Novel Strategies to Personalize CareAug 29, 20181.5
Publication Bottom Border
Border Publication
x